Pulse Biosciences (NASDAQ:PLSE) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report released on Wednesday.

Pulse Biosciences Trading Up 0.3 %

NASDAQ:PLSE opened at $20.37 on Wednesday. The company’s 50-day moving average is $17.18 and its two-hundred day moving average is $15.60. Pulse Biosciences has a 1-year low of $6.59 and a 1-year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the prior year, the business posted ($0.19) EPS.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of PLSE. Vanguard Group Inc. boosted its holdings in Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after purchasing an additional 189,227 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after acquiring an additional 97,565 shares during the last quarter. State Street Corp lifted its holdings in shares of Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after acquiring an additional 69,696 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pulse Biosciences in the 3rd quarter worth approximately $588,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after acquiring an additional 33,200 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.